Profile data is unavailable for this security.
About the company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
- Revenue in USD (TTM)6.86m
- Net income in USD-228.69m
- Incorporated2022
- Employees29.00
- LocationNewAmsterdam Pharma Company NVGooimeer 2-35NAARDEN 1411 DCNetherlandsNLD
- Phone+31 352062971
- Websitehttps://ir.newamsterdampharma.com/